Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001553350-20-000907
Filing Date
2020-10-01
Accepted
2020-10-01 16:41:26
Documents
1

Document Format Files

Seq Description Document Type Size
1 SC 13G l1cap_sc13g.htm SC 13G 38259
  Complete submission text file 0001553350-20-000907.txt   39891
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Subject) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-46083 | Film No.: 201216700
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 161A SHEDDEN ROAD ONE ARTILLARY COURT P.O. BOX 10085 GRAND KAYMAN E9 KY1-1001
Business Address 161A SHEDDEN ROAD ONE ARTILLARY COURT P.O. BOX 10085 GRAND KAYMAN E9 KY1-1001 646-688-5654
L1 Capital Global Opportunities Master Fund, Ltd. (Filed by) CIK: 0001702202 (see all company filings)

EIN.: 981241877 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13G